Angiotensin-converting enzyme (ACE) inhibitors and angio-oedema

British Journal of Dermatology

Volumn 136, Issue 2, 1997, Pages 153-158

  Sabroe, R A ^a   Kobza Black, A ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; BRADYKININ; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; TRANDOLAPRIL;

ANGIONEUROTIC EDEMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; HUMAN; INCIDENCE; INHALATIONAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031047155     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.1997.tb14887.x     Document Type: Review

References (65)

1. Greaves M, Lawlor F. Angioedema: manifestations and management. J Am Acad Dermatol 1991; 25: 155-65.
2. Donaldson VH, Evans RR. A biochemical abnormality in hereditary angioneurotic edema: absence of serum inhibitor of C′1-esterase. Am J Med 1965; 35: 37-44.
3. Rosen FS, Alper CA, Pensky J et al. Genetically determined heterogeneity of the C1 esterase inhibitor in patients with hereditary angioneurotic edema. J Clin Invest 1971; 50: 2145-9.
4. Champion RH, Roberts SOB, Carpenter RG, Roger JH. Urticaria and angio-oedema: a review of 554 patients. Br J Dermatol 1969; 81: 588-97.
5. Gelfand JA, Boss GR, Conley CL et al. Acquired C1 esterase inhibitor deficiency and angioedema; a review. Medicine 1979; 58: 321-8.
6. Wilkin JK, Hammond JJ, Kirkendall WM. The captopril-induced eruption. Arch Dermatol 1980; 116: 902-5.
7. Roberts JR, Wuerz RC. Clinical characteristics of angiotensin-converting enzyme inhibitor-induced angioedema. Ann Emerg Med 1991; 20: 555-8.
8. Finley CJ, Silverman MA, Nunez AE. Angiotensin-converting enzyme inhibitor-induced angioedema: still unrecognized. Am J Emerg Med 1992; 10: 550-2.
9. Inman WHW, Rawson NSB, Wilton LV et al. Postmarketing surveillance of enalapril. I: Results of prescription-event monitering. Br Med J 1988; 297: 826-9.
10. Slater EE, Merrill DD, Guess HA et al. Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition. JAMA 1988; 260: 967-70.
11. Hedner T, Samuelsson O, Lunde H et al. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. Br Med J 1992; 304: 941-6.
12. Megerian CA, Arnold JE, Berger M. Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment. Laryngoscope 1992; 102: 256-60.
13. Oike Y, Ogata Y, Higashi D et al. Fatal angioedema associated with enalapril. Int Med 1993; 32: 308-10.
14. Dyer PD. Late-onset angioedema after interruption of angiotensin converting enzyme inhibitor therapy. J Allergy Clin Immunol 1994; 93: 947-8.
15. Guy C, Cathébras P, Rousset H. Suspected angioedema of abdominal viscera. Ann Intern Med 1994; 121: 900.
16. Matsumura M, Haruki K, Kajinami K, Takada T. Angioedema likely related to angiotensin converting enzyme inhibitors. Int Med 1993; 32: 424-6.
17. Thompson T, Smith-Frable MA. Drug-induced, life threatening angioedema revisited. Laryngoscope 1993; 103: 10-12.
18. Jacobs RL, Hoberman LJ, Goldstein HM. Angioedema of the small bowel caused by an angiotensin-converting enzyme inhibitor. Am J Gastroenterol 1994; 89: 127-8.
19. Wood SM, Mann RD, Rawlins MD. Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors. Br Med J 1987; 294: 91-2.
20. Jain M, Armstrong L, Hall J. Predisposition to and late onset of upper airway obstruction following angiotensin-converting enzyme inhibitor therapy. Chest 1992; 102: 871-4.
21. Verresen L, Waer M, Vanrenterghem Y, Michielsen P. Angiotensin-converting-enzyme inhibitors and anaphylactoid reaction to high-flux membrane dialysis. Lancet 1990; 336: 1360-2.
22. Pigman EC, Scott JL. Angioedema in the Emergency Department: the impact of angiotensin-converting enzyme inhibitors. Am J Emerg Med 1993; 11: 350-4.
23. Orfan N, Patterson R, Dykewicz MS. Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema. JAMA 1990; 264: 1287-9.
24. Chin HL, Buchan DA. Severe angioedema after long-term use of an angiotensin-converting enzyme inhibitor. Ann Intern Med 1990; 112: 312-13.
25. Gannon TH, Eby TL. Angioedema from angiotensin converting enzyme inhibitors: a cause of upper airway obstruction. Laryngoscope 1990; 100: 1156-60.
26. Singer DRJ, MacGregor GA. Angioneurotic oedema associated with two angiotensin converting enzyme inhibitors (letter). Br Med J 1986; 293: 1243.
27. Chu TJ, Chow N. Adverse effects of ACE inhibitors (letter). Ann Intern Med 1993; 118: 314.
28. Agostoni A, Cicardi M. Contraindications to the use of ACE inhibitors in patients with C1 esterase inhibitor deficiency (letter). Am J Med 1991; 90: 278.
29. Kozel MMA, Mekkes JR, Bos JD. Increased frequency and severity of angio-oedema related to long-term therapy with angiotensin-converting enzyme inhibitor in two patients. Clin Exp Dermatol 1995; 20: 60-1.
30. Giannoccaro PJ, Wallace GJ, Higginson LAJ, Williams WL. Fatal angioedema associated with enalapril. Can J Cardiol 1989; 5: 335-6.
31. Cameron HA, Higgins TJC. Clinical experience with lisinopril. Observations on safety and tolerability. J Hum Hypertens 1989; 3: 177-86.
32. Erdös EG. Conversion of angiotensin I to angiotensin II. Am J Med 1976; 60: 749-59.
33. Regoli D, Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol Rev 1980; 32: 1-46.
34. Haddy FJ, Emerson TE, Scott JB, Daughtery RM. The effect of the kinins on the cardiovascular system. In: Handbook of Experimental Pharmacology: Bradykinin, Kallidin and Kallikrein (Erdos EG, ed.), Vol. 25. Berlin: Springer-Verlag, 1970; 362-84.
35. Oyvin IA, Gaponyuk PY, Volodin VM et al. Mechanisms of blood vessel permeability derangement under the influence of permeability factors (histamine, serotonin, kinins) and inflammatory agents. Biochem Pharmacol 1972; 21: 89-95.
36. Rotmensch HH, Vlasses PH, Ferguson RK. Angiotensin-converting enzyme inhibitors. Med Clin N Am 1988; 72: 399-425.
37. Anon. Who needs nine ACE inhibitors? Drug Ther Bull 1995; 33: 1-3.
38. Sever P, Beevers G, Bulpitt C et al. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. Br Med J 1993; 306: 983-7.
39. Edwards CRW, Padfield PL. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet 1985; i: 30-4.
40. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 525: 293-302.
41. McMurray J, Rankin A. Cardiology - I. Treatment of myocardial infarction, unstable angina, and angina pectoris. Br Med J 1994; 309: 1343-50.
42. Parving HH, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. Br Med J 1988; 297: 1086-91.
43. Hannedouche T, Landais P, Goldfarb B et al. Randomised controlled trial of enalapril and β blockers in non-diabetic chronic renal failure. Br Med J 1994; 309: 833-7.
44. Croog SH, Levine S, Testa MA et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657-64.
45. Weber MA. Safety issues during antihypertensive treatment with angiotensin converting enzyme inhibitors. Am J Med 1988; 84 (Suppl. 4A): 16-23.
46. Reinhardt LA, Wilkin JK, Kirkendall WM. Lichenoid eruption produced by captopril. Cutis 1983; 31: 98-9.
47. Parfrey PS, Clement M, Vandenburg MJ, Wright P. Captopril-induced pemphigus. Br Med J 1980; 281: 194.
48. Solinger AM. Exfoliative dermatitis from captopril. Cutis 1982; 29: 473-4.
49. Brueggemeyer CD, Ramirez G. Onycholysis associated with captopril. Lancet 1984; i: 1352-3.
50. Bönner G, Preis S, Schunk U et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol 1990; 15 (Suppl. 6): S46-S56.
51. Nasjletti A, Colina Chourio J, McGiff JC. Disappearance of bradykinin in the renal circulation of dogs: effects of kininase inhibition. Circ Res 1975; 37: 59-65.
52. Ferreira SH, Rocha e Silva M. Potentiation of bradykinin and eledoisin by BPF (bradykinin potentiating factor) from Bothrops jararaca venom. Experientia 1965; 21: 347-9.
53. Anderson MW, deShazo RD. Studies of the mechanism of angiotensin-converting enzyme (ACE) inhibitor-associated angioedema: the effect of an ACE inhibitor on cutaneous responses to bradykinin, codeine, and histamine. J Allergy Clin Immunol 1990; 85: 856-8.
54. Li Kam Wa TC, Cooke ED, Turner P. A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm. Br J Clin Pharmacol 1993; 35: 8-13.
55. Atlas SA, Case DB, Yu ZY, Laragh JH. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors: possible differences between enalapril and captopril. Am J Med 1984; 77 (Suppl. 2A): 13-17.
56. Mathews KP, Pan PM, Gardner NJ, Hugli TE. Familial carboxypeptidase N deficiency. Ann Intern Med 1980; 93: 443-5.
57. Erdös EG. Some old and some new ideas on kinin metabolism. J Cardiavasc Pharmacol 1990; 15 (Suppl. 6): S20-S4.
58. Auchincloss JH, Streeten DHP, Gilbert R, Peppi D. Dyspnea in patients with hyperbradykininism and excessive venous pooling. Am J Med 1986; 81: 260-6.
59. Foreman JC. Neuropeptides and the pathogenesis of allergy. Allergy 1987; 42: 1-11.
60. Cascieri MA, Bull HG, Mumford RA et al. Carboxyl-terminal tripeplidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422. Mol Pharmacol 1984; 25: 287-93.
61. Lindgren BR, Persson K, Kihlström JE, Andersson RGG. ACE-inhibitor-induced enhancement of spontaneous and IgE-mediated histamine release from mast cells and basophilic leukocytes and the modulatory effect of capsaicin sensitive nerves. Pharmacol Toxicol 1989; 64: 159-64.
62. Soter NA. Acute and chronic urticaria and angioedema. J Am Acad Dermatol 1991; 25: 146-54.
63. Cooper KD. Urticaria and angioedema: diagnosis and evaluation. J Am Acad Dermatol 1991; 25: 166-76.
64. Brown NJ, Nadeau JH. Does race predispose to angiotensin-associated angioneurotic edema? Ann Intern Med 1993; 119: 1224.
65. Kaplan NM. Ethnic aspects of hypertension. Lancet 1994; 344: 450-2.